Printed from Voxsanity (voxsanity.com.au) — NCT07117877 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
NCT07117877
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 to 75 years old.
- There are measurable areas of cancer visible on scans at the start of the trial, assessed using a standard measurement system called RECIST 1.1.
- The person is reasonably active and able to care for themselves, based on a standard performance scale scored 0 or 1 (confirm with trial site).
- Diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back and is no longer responding well to platinum-based chemotherapy (either stopped working during treatment or came back within 6 months of finishing it).
- 10 tissue sample slides must be provided for testing to confirm the cancer type and explore treatment markers.
- Has received at least 1 but no more than 6 rounds of systemic (whole-body) cancer treatment overall, and no more than 4 rounds after the cancer became resistant to platinum-based chemotherapy.
- Previous treatment must have included at least one platinum-based chemotherapy course, with specific timing requirements depending on how many lines of treatment were received (confirm with trial site).
- The cancer progressed (got worse) after the most recent systemic treatment received.
- Blood counts are within acceptable ranges without recent transfusions or blood-stimulating medications in the past 14 days: haemoglobin, white blood cell count, and platelet levels must meet specific minimum values (confirm with trial site).
- Liver and kidney function test results are within acceptable ranges, including liver enzymes, bilirubin, and creatinine levels (confirm with trial site).
- Blood clotting function test results are within acceptable ranges (confirm with trial site).
- Urine protein levels are low enough — either below a certain level on a standard urine test, or confirmed below 1g in a 24-hour urine collection if the initial result is borderline.
- Heart function is adequate, with the heart pumping at least 50% of its capacity as measured by ultrasound.
- Women who could become pregnant must use two medically approved forms of contraception during the study and for 3 months after treatment ends, must not be breastfeeding, and must have a negative pregnancy blood test within 72 hours before the first dose.
- The person voluntarily agrees to join the study, signs a consent form, is willing to follow the study requirements, and agrees to attend follow-up appointments.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently taking part in another clinical trial at the same time.
- People with a history of severe drug allergies or allergic reactions, or who are known to be allergic or intolerant to the study drug.
- People who do not have measurable areas of cancer on scans, or whose cancer cannot be properly assessed.
- People with cancer that has spread to the brain or the lining of the brain that has not yet been treated — however, people who have previously received treatment for brain or meningeal metastases, have been confirmed stable for at least one month on scans, and have stopped high-dose steroid treatment for more than two weeks without symptoms may still be considered (confirm with trial site).
- People who are unable to swallow tablets or capsules normally, or who have digestive system problems that doctors believe may prevent the drug from being absorbed properly.
- People who have had a bowel obstruction in the past 3 months.
- People who currently have uncontrollable fluid build-up around the lungs, in the abdomen, or around the heart that cannot be managed effectively with medication or drainage procedures.
- People with uncontrolled ongoing health conditions, including but not limited to: active hepatitis B or C infection; known HIV infection or AIDS; active syphilis; active tuberculosis; active infection; uncontrolled high blood pressure; symptomatic heart failure; or active bleeding.
- People with a history of certain blood cancers (myelodysplastic syndrome or acute myeloid leukaemia) or other serious cancers within the 5 years before starting the study (with some exceptions for fully resolved or very slow-growing cancers, as determined by the doctor).
- People who have had another cancer that was not curable in the past 5 years or currently have one — exceptions may apply for certain treated skin cancers, cervical cancer in early stages, or breast cancer with no recurrence for more than 3 years after definitive surgery (confirm with trial site).
- Women who are pregnant or breastfeeding.
- People who, in the opinion of the research team, have other serious conditions — including serious mental illness, significantly abnormal lab results, or significant family or social circumstances — that could put them at risk or affect the quality of the study data.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 021-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
15 September 2025
Est. completion
31 August 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.